Minimal residual disease in multiple myeloma
- PMID: 23733782
- PMCID: PMC5321086
- DOI: 10.1200/JCO.2013.49.2124
Minimal residual disease in multiple myeloma
Comment on
-
Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.J Clin Oncol. 2013 Jul 10;31(20):2540-7. doi: 10.1200/JCO.2012.46.2119. Epub 2013 Jun 3. J Clin Oncol. 2013. PMID: 23733781 Clinical Trial.
References
-
- Mahindra A, Laubach J, Raje N, et al. Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol. 2012;9:135–143. - PubMed
-
- Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046–1060. - PubMed
-
- Anderson KC. Oncogenomics to target myeloma in the bone marrow microenvironment. Clin Cancer Res. 2011;17:1225–1233. - PubMed
-
- Badros AZ. Lenalidomide in myeloma—a high-maintenance friend. N Engl J Med. 2012;366:1836–1838. - PubMed
-
- Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1782–1791. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical